Current status of therapy of solid tumors: Brain tumor therapy

Journal of Nuclear Medicine

Volumn 46, Issue 1 SUPPL., 2005, Pages

  Zalutsky, Michael R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

131I; 211At; Brain tumor; Glioma; Radionuclide therapy

Indexed keywords

ASTATINE 211; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORODEOXYGLUCOSE F 18; IODINE 131; TENASCIN; YTTRIUM 90; MONOCLONAL ANTIBODY; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT;

ARTICLE; BRACHYTHERAPY; BRAIN TUMOR; CANCER CELL; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER SURVIVAL; CLINICAL TRIAL; DOSIMETRY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; GLIOBLASTOMA; GLIOMA; HISTOPATHOLOGY; HUMAN; NEUROIMAGING; OLIGODENDROGLIOMA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION NECROSIS; RADIOIMMUNOTHERAPY; SCINTISCANNING; SOLID TUMOR; UNSPECIFIED SIDE EFFECT; ANIMAL; CLINICAL PRACTICE; COLON TUMOR; DRUG DELIVERY SYSTEM; METHODOLOGY; PRACTICE GUIDELINE; REVIEW; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; COLONIC NEOPLASMS; DRUG DELIVERY SYSTEMS; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 14844341937     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 2002;359:1011-1018.
2. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and factors in recurrent glioma patients enrolled onto phase II trials. J Clin Oncol. 1999;17:2572-2578.
3. 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. Cancer Res. 1989;49:2807-2813.
4. Burger PC, Heinz ER, Shibata T, Kleihues P. Topographic anatomy and CT correlations in the untreated glioblastoma multiforme. J Neurosurg. 1988;68:698-704.
5. Goldbrunner RH, Bernstein JJ, Tonn, J-C. Cell-extracellular matrix interaction in glioma invasion. Acta Neurochir. 1999;41:295-305.
6. 90Y MoAbs into glioma tumor resection cavities leads to limited diffusion of the radioimmunoconjugates into normal brain parenchyma: a model to estimate absorbed radiation dose. Int J Radiat Oncol Biol Phys. 1998;40:835-844.
7. Kalofonos HP, Pawlikowska TR, Hemingway A, et al. Antibody guided diagnosis and therapy of brain gliomas using radiolabeled monoclonal antibodies against epidermal growth factor receptor and placental alkaline phosphatase. J Nucl Med. 1989;30:1636-1645.
8. Brady LW, Miyamoto C, Woo DV, et al. Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: a phase II trial. Int J Radiat Oncol Biol Phys. 1992;22:225-230.
9. Leins A, Riva P, Lindstedt R, Davidoff MS, Mehraein P, Weis S. Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma. Cancer. 2003;98:2430-2439.
10. Wikstrand CJ, Zalutsky MR, Bigner DD. Therapy of brain tumors with radiolabeled antibodies. In: Liau LM, Becker DP, Cloughsey TF, Bigner DD, eds. Brain Tumor Immunotherapy. Totowa, NJ: Humana Press; 2001:205-229.
11. Herold-Mende C, Mueller MM, Bonsanto MM, Schmitt HP, Kunze S, Steiner HH. Clinical impact and functional aspects of tenascin-C expression during glioma progression. Int J Cancer. 2002;98:362-369.
12. Akabani G, McLendon RE, Bigner DD, Zalutsky MR. Vascular targeted endoradiotherapy of tumors using alpha-particle-emitting compounds: theoretical analysis. Int J Radiat Oncol Biol Phys. 2002;4:1259-1275.
13. Balza E, Siri A, Ponassi M, et al. Production and characterization of monoclonal antibodies specific for different epitopes of human tenascin. FEBS Letters. 1993;332:39-43.
14. Bourdon MA, Wikstrand CJ, Furthmayr H, Matthews TJ, Bigner DD. Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res. 1983;43:2796-2805.
15. 2 fragment delivery to tumor in patients with glioma: comparison of intracarotid and intravenous administration. Cancer Res. 1990;50:4105-4110.
16. Schold SC Jr, Zalutsky MR, Coleman RE, et al. Distribution and dosimetry of I-123-labeled monoclonal antibody 81C6 in patients with anaplastic glioma. Invest Radiol. 1993;28:488-496.
17. Bigner DD, Brown MT, Friedman AH, et al. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. J Clin Oncol. 1998;16:2202-2212.
18. Cokgor I, Akabani G, Kuan C-T, et al. Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. J Clin Oncol. 2000;18:3862-3872.
19. 131I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol. 2002;20:1389-1397.
20. Curran WJ, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993;85:704 -710.
21. Akabani G, Cokgor I, Coleman RE, et al. Dosimetry and dose-response relationships in newly diagnosed patients treated with iodine-131-labeled anti-tenascin monoclonal antibody therapy. Int J Radiat Oncol Biol Phys. 2000;46:947-958.
22. 131I- labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors. J Nucl Med. 1999;40:631-638.
23. Riva P, Franceschi G, Riva N, Casi M, Santimaria M, Adamo M. Role of nuclear medicine in the treatment of malignant gliomas: the locoregional radioimmunotherapy approach. Eur J Nucl Med. 2000;27:601-609.
24. Goetz C, Riva P, Poepperl G, et al. Locoregional radioimmunotherapy in selected patients with malignant glioma: experiences, side effects and survival times. J Neurooncol. 2003;62:321-328.
25. Zalutsky MR, Vaidyanathan G. Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle therapy. Current Pharm Design. 2000;6:1433-1455.
26. Zalutsky M, Reardon D, Akabani G, et al. Astatine-211 labeled human/mouse chimeric anti-tenascin monoclonal antibody via surgically created resection cavities for patients with recurrent glioma: Phase I study [abstract]. Neuro-oncol. 2002;4(suppl):S103.
27. Reist CJ, Bigner DD, Zalutsky MR. Human IgG2 constant region enhances in vivo stability of anti-tenascin antibody 81C6 compared with its murine parent. Clin Cancer Res. 1998;4:2495-2502.
28. Nguyen TT, Pannu YS, Sung C, et al. Convective distribution of macromolecules in the primate brain demonstrated using computerized tomography and magnetic resonance imaging. J Neurosurg. 2003;98:584-590.
29. Grossi PM, Ochiai H, Archer GE, et al. Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. Clin Cancer Res. 2003;9:5514-5520.
30. Laske DW, Youle RJ, Oldfield EH. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nature Med. 1997;3:1362-1368.
31. 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study. Eur J Nucl Med. 2002;29:486-493.